Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340905 | 0.88 | KMT2A (0.64) | KMT2AMEN1ALDH1A1KDM4ERAB9A | |
| SCHEMBL26921192 | 0.84 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1RAB9AMAPT | |
| SCHEMBL7094214 | 0.84 | ALDH1A1 (0.68) | KMT2AALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL2616165 | 0.83 | MEN1 (0.69) | KMT2AMEN1ALDH1A1KDM4ERAB9A | |
| SCHEMBL6035088 | 0.83 | ALDH1A1 (0.61) | KMT2AMEN1ALDH1A1KDM4ERAB9A | |
| SCHEMBL2548153 | 0.83 | ALDH1A1 (0.57) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL20421677 | 0.83 | MEN1 (0.47) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL28143892 | 0.83 | MEN1 (0.47) | KMT2AMEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL1189519 | 0.83 | ALDH1A1 (0.63) | KMT2AMEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL26921088 | 0.83 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326710-B2 | Aralkyl formyl-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2008-02-05 | — | — | US | claimed |
| US-20050153981-A1 | Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-07-14 | — | — | US | claimed |
| EP-1553092-A1 | ARALKYL FORMYL-ALKYL PIPERAZINE DERIVATIVES AND THEIR USES AS CEREBRAL NERVE PROTECTIVE AGENT | Shanghai Institute of Pharmaceutical Industry (CN) | 2005-07-13 | — | — | EP | claimed |
| CN-1381448-A | Aralkylformylalkyl piperazine derivative and its application as brain nerve protector | SHANGHAI ACADEMY OF MEDICAL IN (CN) | 2002-11-27 | — | — | CN | claimed |
| US-7326710-B2 | Aralkyl formyl-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2008-02-05 | — | — | US | disclosed |
| US-7078407-B2 | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20050153981-A1 | Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-07-14 | — | — | US | disclosed |
| EP-1553092-A1 | ARALKYL FORMYL-ALKYL PIPERAZINE DERIVATIVES AND THEIR USES AS CEREBRAL NERVE PROTECTIVE AGENT | Shanghai Institute of Pharmaceutical Industry (CN) | 2005-07-13 | — | — | EP | disclosed |
| CN-1181065-C | Aralkylformylalkyl piperazine derivative and its application as brain nerve protector | �Ϻ�ҽҩ��ҵ�о�Ժ | 2004-12-22 | — | — | CN | disclosed |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | disclosed |
| EP-0901469-B1 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | UNIV MONASH (AU) | 2003-08-27 | — | — | EP | disclosed |
| CN-1381448-A | Aralkylformylalkyl piperazine derivative and its application as brain nerve protector | SHANGHAI ACADEMY OF MEDICAL IN (CN) | 2002-11-27 | — | — | CN | disclosed |
| US-6232314-B1 | SUCH AS 1-(2-(4-CHLOROPHENYL)-2-HYDROXY)ETHYL-4-(3,5-BIS(1,1-DIMETHYLETHYL)-4 -HYDROXYPHENYL)METHYLPIPERAZINE; USED TO TREAT STROKE, CARDIAC ARREST, ISCHAEMIA, HYPOXIA, HYPOGLYCAEMIA, EPILEPSY, AND AMYOTROPHIC LATERAL SCLEROSIS | MONASH UNIVERSITY (AU) | 2001-05-15 | — | — | US | disclosed |
| EP-0901469-A4 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | UNIV MONASH (AU) | 2000-11-15 | — | — | EP | disclosed |
| EP-0901469-A1 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | MONASH UNIVERSITY (AU) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043259-A1 | ARYLALKYLPIPERAZINE COMPOUNDS AS ANTIOXIDANTS | MONASH UNIVERSITY (AU) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153981-A1 | Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | GAP43, FABP7, AGK | KMT2A 3987/4885MEN1 4248/4885ALDH1A1 1828/4885 |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | HTT, PARK7, NQO1 | KMT2A 1377/4885MEN1 3297/4885ALDH1A1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.